These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 30304645)
1. Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. Bientinesi R; Sacco E Expert Opin Pharmacother; 2018 Dec; 19(18):1989-1997. PubMed ID: 30304645 [TBL] [Abstract][Full Text] [Related]
2. Urinary incontinence in men: current and developing therapy options. Burden H; Abrams P Expert Opin Pharmacother; 2016; 17(5):715-26. PubMed ID: 26800277 [TBL] [Abstract][Full Text] [Related]
3. A drug safety evaluation of mirabegron in the management of overactive bladder. Robinson D; Thiagamoorthy G; Cardozo L Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445 [TBL] [Abstract][Full Text] [Related]
4. Mirabegron for overactive bladder syndrome. Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821 [TBL] [Abstract][Full Text] [Related]
5. Current and future pharmacotherapy for treating overactive bladder. Thiagamoorthy G; Cardozo L; Robinson D Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972 [TBL] [Abstract][Full Text] [Related]
6. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Thiagamoorthy G; Giarenis I; Cardozo L Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923 [TBL] [Abstract][Full Text] [Related]
7. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Sacco E; Bientinesi R; Tienforti D; Racioppi M; Gulino G; D'Agostino D; Vittori M; Bassi P Expert Opin Drug Discov; 2014 Apr; 9(4):433-48. PubMed ID: 24559030 [TBL] [Abstract][Full Text] [Related]
8. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659 [TBL] [Abstract][Full Text] [Related]
9. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects. Giarenis I; Robinson D; Cardozo L Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom. Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605 [TBL] [Abstract][Full Text] [Related]
11. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Blais AS; Nadeau G; Moore K; Genois L; Bolduc S Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327 [TBL] [Abstract][Full Text] [Related]
12. Mirabegron: A Review in Overactive Bladder Syndrome. Deeks ED Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204 [TBL] [Abstract][Full Text] [Related]
14. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366 [TBL] [Abstract][Full Text] [Related]
15. Mirabegron for the treatment of overactive bladder. Gras J Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458 [TBL] [Abstract][Full Text] [Related]
16. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. Tyagi P; Tyagi V IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. Chapple C; Khullar V; Nitti VW; Frankel J; Herschorn S; Kaper M; Blauwet MB; Siddiqui E Eur Urol; 2015 Jan; 67(1):11-14. PubMed ID: 25092537 [TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment? Kobayashi M; Nukui A; Kamai T Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939 [TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]